Understanding Financial Conflicts of Interest in Cancer Care and Research

Financial conflicts of interest in research exist when a researcher’s—or an institution’s—financial relationships could potentially affect the conduct, interpretation, or reporting of research. Examples of situations in which individuals or groups receive financial compensation include consulting fees, industry-sponsored trials, or royalties linked to the product being studied.

In healthcare, financial conflicts of interest can compromise patient outcomes and public trust. For instance, several studies have found that physicians with financial conflicts of interest are more likely to prescribe the drug involved. Recent data suggest that U.S. physicians receive about $1 billion per year from industry. How would patients feel if they knew that these financial ties might influence their doctor’s recommendations?

There is a growing recognition that modern healthcare and biomedical research are deeply intertwined with commercial funding. Pharmaceutical, device, diagnostics, and health technology companies all play major roles in developing therapies, sponsoring trials, and supporting professional education. That partnership can accelerate innovation, but it also creates pressures that may influence which research projects are funded, how studies are designed and analyzed, how results are framed, and how evidence is translated into guidelines and practice.

In oncology, where drugs are so pricey that they are unaffordable for many patients, treatment decisions are complex and often based on imperfect evidence. Small biases can meaningfully shape what clinicians recommend and what patients receive. The stakes are high.

Working with amazing students Colin Kim, of Yale College, and Lily Wadel, of Yale School of Medicine, our comprehensive systematic review of 36 studies spanning six key domains—clinical trials, U.S. Food and Drug Administration (FDA) advisory meetings, academic medical leaders, patient advocacy organizations, clinical practice guideline authors, and practicing oncologists—found that financial conflicts of interest exceed 50% prevalence across virtually every level of the U.S. oncology landscape.

The findings are striking in scope: Industry sponsorship was present in 69% of cancer clinical trials, and 61% of practicing oncologists received industry payments. Prevalence among academic medical leaders and guideline authors reached as high as 100% in some studies. Financial conflicts have become the norm, from the original clinical trials to regulatory decisions to writing guidelines to recommending treatments at the bedside.

Research on financial conflicts of interest in medicine, including oncology-focused studies, suggests the most consistent influences are found in research outputs and downstream clinical behavior. A previous study by our team showed that studies with industry ties were more likely to yield pro-industry outcomes. Other studies have demonstrated that financial conflicts of interest are associated with biased study design and altered publication and reporting dynamics.

Financial relationships with manufacturers are associated in many studies with higher prescribing of brand-name drugs, faster uptake of new products, and sometimes less guideline-concordant choices—raising costs without improving quality.